Compare CWCO & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CWCO | MYGN |
|---|---|---|
| Founded | 1973 | 1991 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Water Supply | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 478.2M | 444.2M |
| IPO Year | 1997 | 1996 |
| Metric | CWCO | MYGN |
|---|---|---|
| Price | $28.99 | $3.20 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $40.00 | $7.64 |
| AVG Volume (30 Days) | 71.9K | ★ 1.8M |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.73% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.48 | N/A |
| Revenue | $132,073,368.00 | ★ $771,400,000.00 |
| Revenue This Year | $4.34 | $6.86 |
| Revenue Next Year | $42.86 | $5.45 |
| P/E Ratio | $60.25 | ★ N/A |
| Revenue Growth | N/A | ★ 2.33 |
| 52 Week Low | $28.17 | $2.74 |
| 52 Week High | $39.12 | $8.59 |
| Indicator | CWCO | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 40.16 | 39.24 |
| Support Level | $28.78 | $2.79 |
| Resistance Level | $30.68 | $3.31 |
| Average True Range (ATR) | 0.78 | 0.18 |
| MACD | -0.16 | 0.09 |
| Stochastic Oscillator | 7.56 | 69.90 |
Consolidated Water Co Ltd is a water utility company. It develops and operates seawater desalination plants and water distribution systems. The company's business segments are; The retail segment operates the water utility for the Seven Mile Beach and West Bay areas of Grand Cayman Island, The bulk segment supplies potable water to government utilities in Grand Cayman and The Bahamas under long-term contracts, The services segment designs, constructs and sells water infrastructure and provides management and operating services to third parties. The manufacturing segment manufactures and services a wide range of custom and specialized water-related products applicable to commercial, municipal, and industrial water production, supply, and treatment, and the corporate segment.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.